Degludec-first of a new generation of insulins

Abstract

Diabetes is associated with several serious chronic complications, impacting quality of life and health costs and decreasing survival. These complications can be reduced by obtaining an adequate glycaemic control. The use of current insulin preparations, however, is associated with many disadvantages, leading to suboptimal use and hence decreased efficacy. Therefore, there is an urgent need for new types of basal insulin analogues, providing a very stable and long basal insulin supply. Degludec and Degludecplus, a combination of degludec and a short-acting insulin analogue, are the first developed new insulin formulations fulfilling these criteria. Promising Phase II and preliminary Phase III data have shown that this new therapy is both efficacious and safe. In combination with a healthy lifestyle, this new generation of insulin might become the new standard of care in type 1 and 2 diabetes, reducing both fatal and non-fatal complications and improving quality of life. © Touch Briefings 2011.